Meta AnalysisID 7044
木橘（Aegle marmelos）在调节与肝脏和胆囊疾病相关的多种生物标志物中的有效性：一项系统评价和Meta分析
CRD42023465969
Is Bael (Aegle marmelos) a viable natural alternative to adjust the biomarkers of Liver and Gall bladder in clinical way, and improve its functions.
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Herb: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 7044
- Evidence Id
- 15602
- Core Evidence Id
- 15602
- Source Meta Analysis Id
- 7026
- Herb2 Meta Analysis Id
- HBMA007026
- Crd Id
- CRD42023465969
- Title
- Effectiveness of Bael (Aegle marmelos) in regulating various biomarkers related to Liver and Gall bladder diseases: A systematic review and meta analysis
- Review Question
- Is Bael (Aegle marmelos) a viable natural alternative to adjust the biomarkers of Liver and Gall bladder in clinical way, and improve its functions.
- Study Type Included
- RCTs (Pilot, phase (I, II, and III)), RWE studies (Observational study, , case review, case report, cross-sectional, cohort, case control etc), single arm RCT, Quasi RCT, qualitative study will be included. Pre-clinical trial, review article, pooled analysis, letter to editor, and non-peer reviewed articles, SRMA, pre-print will be excluded.
- Condition Being Studied
- Liver disease accounts for approximately 2 million deaths per year worldwide, 1 million due to complications of cirrhosis and 1 million due to viral hepatitis and hepatocellular carcinoma. Cirrhosis is currently the 11th most common cause of death globally and liver cancer is the 16th leading cause of death; combined, they account for 3.5% of all deaths worldwide. Cirrhosis is within the top 20 causes of disability-adjusted life years and years of life lost, accounting for 1.6% and 2.1% of the worldwide burden. Gallstone disease affects more than 20 million people in the United States. One million patients are newly diagnosed with gallstone disease, of which 50–70% are asymptomatic at diagnosis. Both the organs are vital in proper functioning of body, with treatment usually been expensive hence there is a need for natural alternative. Bael has been used in Asia subcontinent for centuries and its efficacy has been well recorded. But the studies are scattered and combined effectiveness has yet not been reported, hence we are trying to bring the effectiveness of bael in liver and gall bladder disease.
- Participant
- Patients with liver or gallbladder disease, with or without any other disease or co-morbidity, aged ≥5 years, of either sexes are eligible. Animals, cadaver, children <5 years of age are not eligible.
- Animal
- Human Disease Modelled
- Intervention
- Bael (aegle marmelos, stone apple, etc) in any formulation, dosage, or duration as stand-alone therapy, or in combination with other medication and therapy will be included. Studies with no Bael intervention shall be excluded.
- Comparator Control
- Bael (aegle marmelos, stone apple, etc) in any formulation, dosage, or duration as stand-alone therapy, or in combination with other medication or therapy. Any other therapy or medication, placebo, or active control will be included. No reason for exclusion.
- Main Outcome
- The following biomarkers levels will be checked following the intervention, Biomarkers: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP), Gamma-Glutamyl Transferase (GGT), Bilirubin (and it different forms), Albumin, Prothrombin Time (PT) and International Normalized Ratio (INR), Alpha-Fetoprotein (AFP), Fibrosis Biomarkers [Direct biomarkers (e.g., Type IV collagen, matrix metalloproteinases, hyaluronic acid and other glycoproteins, cytokines such as TGF-β1, PDGF, Microfibril associated protein-4); Indirect markers (e.g., Prothrombin time, albumin, bilirubin, AST, ALP, ALT)], HBsAg, anti-HCV, HDL, LDL, VLDL, Antinuclear antibodies (ANA) - Anti-smooth muscle antibodies (SMA), Antimitochondrial antibodies (AMA). Measures of effect Mean difference (MD) and percentage points of change of biomarkers will be the measures of effects. Measures other than MD will be converted using appropriate formulae as outlined and indicated in the meta-analysis textbook ( Michael Borenstein, Larry V. Hedges, Julian P. T. Higgins, Hannah R. Rothstein (2008). Introduction to Meta‐Analysis.)
- Outcome Measure
- Additional Outcome
- Not applicable Measures of effect Not applicable
- Study Method
- Meta-analysis, Systematic review
- Keyword
- MeSH headings have not been applied to this record
- Contact
- SHUBHAM SHARMA [email protected]
- Organisational Affiliation
- Indian Institute of Public Health, Gandhinagar
- Funding Source
- None Grant number(s) State the funder, grant or award number and the date of award NA
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- India
- Review Stage
- Review Ongoing
- First Submission Date
- 2023-09-25
- Registration Date
- 2023-10-06
- Anticipated Start Date
- 2023-09-22
- Anticipated Completion Date
- 2024-04-30
- Title Cn
- 木橘（Aegle marmelos）在调节与肝脏和胆囊疾病相关的多种生物标志物中的有效性：一项系统评价和Meta分析
- Title En
- Effectiveness of Bael (Aegle marmelos) in regulating various biomarkers related to Liver and Gall bladder diseases: A systematic review and meta analysis
- Bilingual Status
- complete